利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.017 秒)

    Anti-HLA-DR antibody
    1.
    发明授权
    Anti-HLA-DR antibody 失效
    抗HLA-DR抗体

    公开(公告)号：US07262278B2

    公开(公告)日：2007-08-28

    申请号：US10469304

    申请日：2002-10-15

    申请人： Tomonori Tawara ,  Shiro Kataoka

    发明人： Tomonori Tawara ,  Shiro Kataoka

    IPC分类号： C12P21/08 ,  C07K16/28

    CPC分类号： C07K16/2833 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/734

    摘要： This invention provides an anti-HLA-DR monoclonal antibody. This invention relates to an antibody binding to HLA-DR or a functional fragment thereof having (a) life-extending effects in nonhuman animals bearing HLA-DR-expressing cancer cells and (b) activity of suppressing immune responses lower than that of L243, or an antibody binding to HLA-DR or a functional fragment thereof exhibiting immunosuppressive activity equivalent to or higher than that of the mouse anti-HLA-DR monoclonal antibody L243 (ATCC HB-55).

    摘要翻译： 本发明提供抗HLA-DR单克隆抗体。 本发明涉及与HLA-DR结合的抗体或其功能片段，其具有（a）带有表达HLA-DR的癌细胞的非人动物的延续效应，和（b）抑制免疫应答的活性低于L243， 或与HLA-DR结合的抗体或其表现与小鼠抗HLA-DR单克隆抗体L243（ATCC HB-55）的免疫抑制活性相当或更高的免疫抑制活性的功能片段。

    ANTI-TIM-3 ANTIBODY
    4.
    发明申请
    ANTI-TIM-3 ANTIBODY 有权
    抗TIM-3抗体

    公开(公告)号：US20120189617A1

    公开(公告)日：2012-07-26

    申请号：US13158622

    申请日：2011-06-13

    申请人： Shin-ichiro TAKAYANAGI ,  Hitomi TOMURA ,  Tomonori TAWARA ,  Yoshimasa INAGAKI ,  Tsuguo KUBOTA ,  Koichi AKASHI ,  Yoshikane KIKUSHIGE

    发明人： Shin-ichiro TAKAYANAGI ,  Hitomi TOMURA ,  Tomonori TAWARA ,  Yoshimasa INAGAKI ,  Tsuguo KUBOTA ,  Koichi AKASHI ,  Yoshikane KIKUSHIGE

    IPC分类号： A61K39/395 ,  C12N15/13 ,  C12N15/63 ,  G01N21/64 ,  C12P21/08 ,  G01N33/53 ,  C12N1/21 ,  C07K16/18 ,  C12N5/10

    CPC分类号： C07K16/2803 ,  C07K16/2818 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92 ,  G01N33/56972

    摘要： The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure thereof and exhibits higher effector activity such as an antibody-dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient. In addition, the present invention provides an anti-human TIM-3 antibody having high ADCC activity by screening an anti-human TIM-3 antibody which competes with the monoclonal antibody or the antibody fragment thereof.

    摘要翻译： 本发明提供了结合TIM-3细胞外区域的氨基酸序列或其三维结构的抗人TIM-3抗体，并表现出更高的效应子活性，例如抗体依赖性细胞毒性（ADCC活性 ）用于与TIM-3表达细胞相关的疾病。 本发明提供了结合TIM-3细胞外区域的氨基酸序列或其三维结构并表现出ADCC活性的单克隆抗体或其抗体片段; 产生抗体的杂交瘤; 编码抗体的DNA; 包含DNA的载体; 通过引入载体可获得的转化体; 包括使用该杂交瘤或转化体的抗体或其抗体片段的制备方法; 包含抗体或其抗体片段的治疗剂和诊断剂作为活性成分。 此外，本发明通过筛选与单克隆抗体或其抗体片段竞争的抗人TIM-3抗体，提供具有高ADCC活性的抗人TIM-3抗体。